Symphogen starts Phase 2 trial in SCCHN patients
The trial will evaluate Sym004 in patients suffering from recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The Phase 2 trial aims at progression
Biointron Biological has launched RushData, a new platform to support the process of antibody discovery for pharmaceutical and biotechnology companies employing AI and machine learning (ML).